Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system
- PMID: 21034228
- PMCID: PMC4845674
- DOI: 10.1089/thy.2010.0178
Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system
Abstract
Background: A risk-adapted approach to management of thyroid cancer requires risk estimates that change over time based on response to therapy and the course of the disease. The objective of this study was to validate the American Thyroid Association (ATA) risk of recurrence staging system and determine if an assessment of response to therapy during the first 2 years of follow-up can modify these initial risk estimates.
Methods: This retrospective review identified 588 adult follicular cell-derived thyroid cancer patients followed for a median of 7 years (range 1-15 years) after total thyroidectomy and radioactive iodine remnant ablation. Patients were stratified according to ATA risk categories (low, intermediate, or high) as part of initial staging. Clinical data obtained during the first 2 years of follow-up (suppressed thyroglobulin [Tg], stimulated Tg, and imaging studies) were used to re-stage each patient based on response to initial therapy (excellent, acceptable, or incomplete). Clinical outcomes predicted by initial ATA risk categories were compared with revised risk estimates obtained after response to therapy variables were used to modify the initial ATA risk estimates.
Results: Persistent structural disease or recurrence was identified in 3% of the low-risk, 21% of the intermediate-risk, and 68% of the high-risk patients (p < 0.001). Re-stratification during the first 2 years of follow-up reduced the likelihood of finding persistent structural disease or recurrence to 2% in low-risk, 2% in intermediate-risk, and 14% in high-risk patients, demonstrating an excellent response to therapy (stimulated Tg < 1 ng/mL without structural evidence of disease). Conversely, an incomplete response to initial therapy (suppressed Tg > 1 ng/mL, stimulated Tg > 10 ng/mL, rising Tg values, or structural disease identification within the first 2 years of follow-up) increased the likelihood of persistent structural disease or recurrence to 13% in low-risk, 41% in intermediate-risk, and 79% in high-risk patients.
Conclusions: Our data confirm that the newly proposed ATA recurrence staging system effectively predicts the risk of recurrence and persistent disease. Further, these initial ATA risk estimates can be significantly refined based on the assessment of response to initial therapy, thereby providing a dynamic risk assessment that can be used to more effectively tailor ongoing follow-up recommendations.
Similar articles
-
Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.Arch Endocrinol Metab. 2024 Apr 4;68:e220506. doi: 10.20945/2359-4292-2022-0506. Arch Endocrinol Metab. 2024. PMID: 38578436 Free PMC article.
-
Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.Thyroid. 2017 Apr;27(4):531-536. doi: 10.1089/thy.2016.0479. Epub 2017 Jan 23. Thyroid. 2017. PMID: 28007013
-
Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.Thyroid. 2013 Nov;23(11):1401-7. doi: 10.1089/thy.2013.0011. Epub 2013 Jul 25. Thyroid. 2013. PMID: 23517313
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
-
Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.Thyroid. 2000 Sep;10(9):767-78. doi: 10.1089/thy.2000.10.767. Thyroid. 2000. PMID: 11041454 Review.
Cited by
-
An Executive Summary of The Philippine Interim Clinical Practice Guidelines for the Diagnosis and Management of Well Differentiated Thyroid Cancer 2021.Acta Med Philipp. 2024 May 15;58(8):5-30. doi: 10.47895/amp.vi0.6535. eCollection 2024. Acta Med Philipp. 2024. PMID: 38812767 Free PMC article.
-
Clinical inertia in thyrotropin suppressive therapy for low-risk differentiated thyroid cancer: A real-world experience at an endocrine center in Bangkok.Medicine (Baltimore). 2024 May 24;103(21):e38290. doi: 10.1097/MD.0000000000038290. Medicine (Baltimore). 2024. PMID: 38788029 Free PMC article.
-
Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.Endocrine. 2024 May 2. doi: 10.1007/s12020-024-03844-x. Online ahead of print. Endocrine. 2024. PMID: 38696058
-
Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.Arch Endocrinol Metab. 2024 Apr 4;68:e220506. doi: 10.20945/2359-4292-2022-0506. Arch Endocrinol Metab. 2024. PMID: 38578436 Free PMC article.
-
Differentiated thyroid carcinoma: what the nonspecialists needs to know.Arch Endocrinol Metab. 2024 Feb 29;68:e230375. doi: 10.20945/2359-4292-2023-0375. Arch Endocrinol Metab. 2024. PMID: 38427812 Free PMC article. Review.
References
-
- Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract. 2007;13:521–533. - PubMed
-
- Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13:498–512. - PubMed
-
- Shaha AR. Shah JP. Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol. 1997;4:328–333. - PubMed
-
- Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract. 2008;14:764–774. - PubMed
-
- Cooper DS. Doherty GM. Haugen BR. Kloos RT. Lee SL. Mandel SJ. Mazzaferri EL. McIver B. Pacini F. Schlumberger M. Sherman SI. Steward DL. Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous